Clinical Trial Update: Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Licartin in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Licartin (Iodine-131 metaiodobenzylguanidine)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Unresectable Hepatocellular Carcinoma | Phase 4 | Status: COMPLETED